TNFSF11 and Duchenne muscular dystrophy: Genetic reduction of p65 levels also diminished chronic inflammation and improved DMD muscle physiology [89], and by targeting RANKL (the receptor activator of nuclear factor NF-κB ligand), it alleviated the pathology by increasing the proportion of M2 macrophages and reducing muscle edema and fibrosis [90].